argenx (ARGX) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of argenx (NASDAQ:ARGX) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have $139.00 price objective on the stock.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

A number of other analysts also recently commented on ARGX. Guggenheim assumed coverage on shares of argenx in a report on Friday, February 22nd. They issued a buy rating and a $157.00 target price on the stock. Wedbush boosted their target price on shares of argenx from $131.00 to $144.00 and gave the stock an outperform rating in a report on Friday, March 1st. ValuEngine upgraded shares of argenx from a hold rating to a buy rating in a report on Monday, February 4th. Stifel Nicolaus reiterated a buy rating on shares of argenx in a report on Monday, February 4th. Finally, SunTrust Banks reiterated a buy rating on shares of argenx in a report on Friday, January 18th. Fourteen research analysts have rated the stock with a buy rating, argenx has an average rating of Buy and an average price target of $144.27.

Shares of NASDAQ ARGX traded down $1.80 during midday trading on Wednesday, reaching $118.20. The company’s stock had a trading volume of 213,300 shares, compared to its average volume of 155,347. argenx has a one year low of $63.81 and a one year high of $135.58. The company has a market capitalization of $3.80 billion, a P/E ratio of -50.30 and a beta of 1.12.

Several institutional investors have recently added to or reduced their stakes in ARGX. We Are One Seven LLC purchased a new position in shares of argenx in the fourth quarter worth approximately $27,000. Partner Investment Management L.P. purchased a new position in shares of argenx in the fourth quarter worth approximately $110,000. SG Americas Securities LLC purchased a new position in shares of argenx in the first quarter worth approximately $134,000. Wells Fargo & Company MN purchased a new position in shares of argenx in the first quarter worth approximately $155,000. Finally, JGP Global Gestao de Recursos Ltda. purchased a new position in shares of argenx in the fourth quarter worth approximately $202,000. 63.58% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: What is the NASDAQ?

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.